Cancer Drug Resistance is a quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original researches. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.
All articles published by CDR
are made freely and permanently accessible online immediately from the date of publication. Articles are published under a Creative Commons Attribution 4.0 International License
(CC BY). The CC BY allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source.
Authors retain the copyright of their works as well as the rights to make certain uses of the works.
For more information about the editorial team, please refer to Editorial Board
Journal Information and Statistics
Launch date: 19 March 2018
Publication model: Open access
ISSN 2578-532X (Online)
Digital archive: Portico
Frequency: Quarterly published
Please visit Contact Us
for details about different queries.